Oxeia Biopharmaceuticals has launched an equity crowdfunding campaign on StartEngine to accelerate development of OXE103, a therapy aimed at treating persistent concussion symptoms, a condition with no approved treatments today.
The campaign supports plans to initiate a Phase 2b clinical trial in 2026, positioning OXE103 as a potential first-in-class therapy for millions of patients who continue to suffer long after a concussion.
A Massive Unmet Need in Concussion Care
Each year, an estimated 1.4 to 4.2 million Americans develop persistent symptoms following a concussion.
These patients often experience:
- Chronic headaches lasting months
- Cognitive impairment affecting work and education
- Reduced quality of life well beyond normal recovery timelines
Standard imaging typically shows no structural brain damage. As a result, physicians have little to offer beyond rest, an approach that does not address the underlying metabolic dysfunction believed to drive persistent symptoms.
Phase 2a Data Shows Clinically Meaningful Benefit
OXE103 demonstrated strong early efficacy in a Phase 2a clinical trial conducted at the University of Kansas Medical Center.
Key trial outcomes:
- 85% responder rate in patients treated with OXE103
- 33% responder rate in patients receiving standard care alone
- Significant reductions in symptom severity
- Measurable improvements in patient quality of life
According to Oxeia, this represents the first clinically meaningful improvement demonstrated in patients with persistent concussion symptoms.
Athlete Validation Brings Added Visibility
Former NFL quarterback Alex Smith, whose career was impacted by concussion, joined Oxeia’s board as an investor after reviewing the clinical data.
“I watched teammates deal with symptoms for months with no treatment options,” Smith said. “This is the first time I’ve seen real clinical evidence that a treatment could help patients recover.”
Accelerated Development Path Through Strategic Licensing
Oxeia’s development timeline has been significantly shortened through a licensing agreement with Daiichi Sankyo Pharmaceuticals.
The agreement provides access to:
- Over $100 million in development data
- Clinical experience from 300+ patients treated with ghrelin across multiple indications
This allowed Oxeia to bypass 5–7 years of early-stage safety testing and move directly into Phase 2 efficacy studies.
Phase 2b Trial Planned for 2026
The upcoming Phase 2b study will:
- Enroll 160 patients
- Be conducted at major academic medical centers
- Focus on validating endpoints critical for regulatory approval
According to Oxeia’s leadership, the study could define the regulatory pathway for concussion therapeutics as a whole.
Equity Crowdfunding Details
Public investors can participate through an SEC-qualified Reg CF offering on StartEngine.
Key points:
- Minimum investment: $500
- Funds will support Phase 2b trial execution
- Offering is open to non-accredited investors
About Oxeia Biopharmaceuticals
Headquartered in Boston, Oxeia Biopharmaceuticals is a clinical-stage biotech company focused on developing treatments for persistent concussion symptoms.
The founding team brings a strong track record, with $9 billion in prior combined exits, including:
- Arena Pharmaceuticals’ $6.7B acquisition by Pfizer
- Kythera Biopharmaceuticals’ $2.1B acquisition by Allergan
Bottom Line
Persistent concussion symptoms affect millions, yet remain untreated.
With compelling Phase 2a data, an accelerated development path, and a clear plan for Phase 2b, OXE103 represents one of the most advanced attempts yet to bring a real therapy to this overlooked patient population.
Whether it succeeds will depend on upcoming trials—but for the first time, there is a credible clinical and regulatory path forward.
